Objective To ascertain the use of secondary prevention medications and cardiac
rehabilitation after an acute coronary syndrome (ACS) and the impact on 2-year outcomes …

Background International studies suggest almost half of all major coronary episodes
annually occur in survivors of acute coronary syndrome (ACS). Objective A greater focus on …

Background Acute coronary syndrome (ACS) is a fatal cardiovascular disease caused by
atherosclerotic plaque erosion or rupture and formation of coronary thrombus. The latest …

Objective To evaluate the proportion of patients hospitalised with acute coronary syndrome
(ACS) in Australia and New Zealand who received optimal inpatient preventive care and to …

Background It is widely reported that long-term use of four preventive medications
(antiplatelet agents, angiotensin converting enzyme inhibitor/angiotensin receptor blocker …

Introduction Patients with a history of acute coronary syndrome are particularly susceptible
to further vascular or ischemic events. Effective secondary prevention following acute …

Background Prevention of repeat cardiovascular events is an important means of
addressing the increasing burden of coronary heart disease in China, however there is …

Background/objectives Acute coronary syndromes (ACS) continue to pose a significant
medical and socioeconomic burden worldwide. Optimal management strategy aims to …

Background Structured secondary cardiovascular prevention programs (SSCP) following
acute coronary syndromes (ACS) may reduce major adverse cardiovascular events (MACE) …

Background Secondary preventive drug therapy following acute myocardial infarction (AMI)
is recommended to reduce the risk of new cardiovascular events. The aim of this nationwide …